[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"status-days":3,"theme-cdmo-generics":32,"theme-heat-cdmo-generics":296},[4,18],{"date":5,"taiex_close":6,"taiex_chg":7,"taiex_chg_pct":8,"advancers":9,"decliners":10,"unchanged":11,"stocks":12,"turnover_sum":13,"margin_balance":14,"margin_chg":15,"short_balance":16,"short_chg":17},"2026-10-12",49301.96,-11.480000000003201,-0.00023279657634922568,868,916,158,1971,1044705369816,9174215,2895,175930,1165,{"date":19,"taiex_close":20,"taiex_chg":21,"taiex_chg_pct":22,"advancers":23,"decliners":24,"unchanged":25,"stocks":26,"turnover_sum":27,"margin_balance":28,"margin_chg":29,"short_balance":30,"short_chg":31},"2026-10-13",48341.31,-960.6500000000015,-0.019485026558781926,444,1337,161,1975,1306098703553,9070158,-104057,168869,-7061,{"id":33,"slug":34,"name":35,"category":36,"summary":39,"members":40,"ret_1d":41,"ret_5d":42,"ret_20d":43,"ret_60d":44,"up":45,"down":46,"flat":47,"mcap":48,"turnover":49,"spark":50,"verified_at":107,"updated_at":108,"as_of":19,"description":109,"facts":110,"drivers":120,"trends":124,"index_base_date":128,"published_at":129,"segments":130,"upstream":285,"downstream":286,"changes":293,"chips":294},56,"cdmo-generics","CDMO 與學名藥",{"slug":37,"name":38},"biotech","生技醫療","原料藥、委託開發製造與學名藥，營收比新藥穩定、看產能與國際認證。",11,-0.010119884584519796,0.017855160726189423,0.024036750129855733,-0.005988834621627248,2,9,0,222441163689.5,803668837,[51,52,53,54,55,56,57,58,59,60,61,62,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,53,82,83,84,85,86,87,88,89,90,91,92,53,93,94,95,96,97,98,99,100,97,101,102,103,104,105,106],65.82,66.09,66.86,67.13,66.49,66.43,66.58,65.42,65.35,64.64,64.74,65.75,66.46,66,66.93,67.77,67.8,67.28,67.15,65.84,66.44,66.12,66.6,68.5,68.76,68.1,67.72,67.93,67.62,67.34,67.01,66.74,66.08,66.05,65.85,65.57,65.8,65.58,64.91,65.03,65.69,65.76,66.98,66.62,66.59,67.06,66.32,66.31,67.03,66.85,65.98,66.04,66.65,67.31,67.84,67.16,"2026-10-14","2026-10-14T04:39:47.967341+08:00","這個題材涵蓋藥品產業中偏製造的一段：上游原料藥廠供應活性成分，中游委託開發製造（CDMO）替藥廠開發與量產，學名藥廠在專利到期後推出同成分藥品。國際藥廠委外比例提高、供應鏈分散，讓通過歐美查廠的台廠接到更多訂單。",[111,114,117],{"label":112,"value":113},"商業模式","原料藥銷售、委託製造、學名藥銷售",{"label":115,"value":116},"關鍵門檻","歐美主管機關查廠、品質系統",{"label":118,"value":119},"觀察重點","產能利用率、國際訂單",[121,122,123],"國際藥廠委外生產比例提高","藥品供應鏈分散，減少對單一國家依賴","專利到期帶來學名藥機會",[125,126,127],"透過併購取得產品與產能","生物藥 CDMO 需求成長","學名藥價格競爭與健保藥價調整","2023-12-29","2026-10-14T04:39:48.312544+08:00",[131,177,207,279],{"id":132,"tier":133,"name":134,"description":135,"members":136},163,"upstream","原料藥","藥品的活性成分與中間體。",[137,153,165],{"code":138,"name":139,"role":140,"relevance":141,"note":142,"industry":143,"close":144,"chg_pct":145,"ret_5d":146,"ret_20d":147,"mcap":148,"turnover":149,"signals":150},"1789","神隆","leader","high","高活性原料藥","生技醫療業",19.4,-0.010204081632653295,0.048648648648648596,0.043010752688172005,15340340906.8,8210821,[151,152],"rev_yoy","foreign_buy_5d",{"code":154,"name":155,"role":156,"relevance":141,"note":157,"industry":143,"close":158,"chg_pct":159,"ret_5d":47,"ret_20d":160,"mcap":161,"turnover":162,"signals":163},"4119","旭富","niche","原料藥與中間體",54.3,-0.02513464991023362,-0.06217616580310892,6489318826.2,10329112,[151,164,152],"rev_yoy_3m",{"code":166,"name":167,"role":156,"relevance":141,"note":168,"industry":143,"close":169,"chg_pct":170,"ret_5d":171,"ret_20d":172,"mcap":173,"turnover":174,"signals":175},"4746","台耀","原料藥與委託製造",47.6,-0.011422637590861928,0.0052798310454065245,0.024757804090419944,5724183838.8,30275715,[151,164,176,152],"eps_yoy",{"id":178,"tier":179,"name":180,"description":181,"members":182},164,"midstream","委託開發製造","替藥廠開發配方與量產，含小分子與生物藥。",[183,195],{"code":184,"name":185,"role":140,"relevance":141,"note":186,"industry":143,"close":187,"chg_pct":188,"ret_5d":189,"ret_20d":190,"mcap":191,"turnover":192,"signals":193},"6472","保瑞","藥品委託製造與產品併購",420,-0.005917159763313529,-0.0011890606420926764,0.035758323057953234,53766090000,243896611,[151,164,152,194],"trust_buy_5d",{"code":196,"name":197,"role":156,"relevance":141,"note":198,"industry":143,"close":199,"chg_pct":200,"ret_5d":201,"ret_20d":202,"mcap":203,"turnover":204,"signals":205},"6589","台康生技","生物藥委託開發製造",49.35,-0.014970059880239472,-0.026627218934911268,0.030271398747390377,15154210470.000002,20856588,[151,164,176,152,206],"holders_up",{"id":208,"tier":179,"name":209,"description":210,"members":211},165,"學名藥與特殊學名藥","專利到期後的同成分藥品。",[212,223,235,246,257,269],{"code":213,"name":214,"role":140,"relevance":141,"note":215,"industry":143,"close":216,"chg_pct":217,"ret_5d":218,"ret_20d":219,"mcap":220,"turnover":221,"signals":222},"1795","美時","學名藥與抗癌藥",178,-0.02997275204359673,0.0028169014084507005,0.005649717514124131,48111673400,287439427,[151,164,152,194,206],{"code":224,"name":225,"role":156,"relevance":141,"note":226,"industry":143,"close":227,"chg_pct":228,"ret_5d":229,"ret_20d":230,"mcap":231,"turnover":232,"signals":233},"4105","東洋","癌症用藥與特殊學名藥",82.1,0.003667481662591676,0.04853128991060007,0.06072351421188604,20414165000,87267240,[151,164,176,152,234,206],"foreign_streak_3d",{"code":236,"name":237,"role":156,"relevance":141,"note":238,"industry":143,"close":239,"chg_pct":240,"ret_5d":241,"ret_20d":242,"mcap":243,"turnover":244,"signals":245},"3705","永信","學名藥",60.7,0.00830564784053145,0.07243816254416946,0.08392857142857135,16171875068.1,42305180,[151,164,176,152,234],{"code":247,"name":248,"role":156,"relevance":141,"note":249,"industry":143,"close":250,"chg_pct":251,"ret_5d":252,"ret_20d":253,"mcap":254,"turnover":255,"signals":256},"1720","生達","學名藥與保健品",57.2,-0.005217391304347729,0.02508960573476715,0.01598579040852588,11243557925.6,19191122,[151,164,176],{"code":258,"name":259,"role":156,"relevance":260,"note":261,"industry":143,"close":262,"chg_pct":263,"ret_5d":264,"ret_20d":265,"mcap":266,"turnover":267,"signals":268},"4123","晟德","mid","藥品與生技投資",30.9,-0.01748807631160576,0.0016207455429497752,0.01812191103789118,24906055080,45611069,[151,164,152],{"code":270,"name":271,"role":156,"relevance":260,"note":249,"industry":143,"close":272,"chg_pct":273,"ret_5d":274,"ret_20d":275,"mcap":276,"turnover":277,"signals":278},"3716","中化控股",34,-0.004392386530014503,0.008902077151335286,0.0014727540500736325,5119693174,8285952,[176],{"id":280,"tier":281,"name":282,"description":283,"members":284},166,"downstream","醫院、藥局與國際藥廠","用藥端與委託客戶。",[],[],[287],{"id":288,"slug":289,"name":290,"category":291,"ret_1d":292},55,"new-drugs","新藥研發",{"slug":37,"name":38},-0.02604453744683346,[],{"members":40,"foreign_buy_count":46,"trust_buy_count":45,"holders_up_count":295},3,{"group":297,"key":34,"name":35,"period":298,"ret":41,"stocks":299},"theme","1d",[300,301,302,303,304,305,306,307,308,309,310],{"code":247,"name":248,"ret":251,"mcap":254,"turnover":255,"close":250,"chg_pct":251},{"code":138,"name":139,"ret":145,"mcap":148,"turnover":149,"close":144,"chg_pct":145},{"code":213,"name":214,"ret":217,"mcap":220,"turnover":221,"close":216,"chg_pct":217},{"code":236,"name":237,"ret":240,"mcap":243,"turnover":244,"close":239,"chg_pct":240},{"code":270,"name":271,"ret":273,"mcap":276,"turnover":277,"close":272,"chg_pct":273},{"code":154,"name":155,"ret":159,"mcap":161,"turnover":162,"close":158,"chg_pct":159},{"code":166,"name":167,"ret":170,"mcap":173,"turnover":174,"close":169,"chg_pct":170},{"code":184,"name":185,"ret":188,"mcap":191,"turnover":192,"close":187,"chg_pct":188},{"code":196,"name":197,"ret":200,"mcap":203,"turnover":204,"close":199,"chg_pct":200},{"code":224,"name":225,"ret":228,"mcap":231,"turnover":232,"close":227,"chg_pct":228},{"code":258,"name":259,"ret":263,"mcap":266,"turnover":267,"close":262,"chg_pct":263}]